Related Experiment Videos
GUSTO II trial
1Flinders Medical Centre, Adelaide, SA.
Insights
The GUSTO II trial compares heparin with recombinant hirudin for acute coronary syndromes. This study evaluates antithrombin therapy effectiveness in unstable angina and myocardial infarction patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Acute coronary syndromes (ACS) require effective antithrombin therapy.
- Heparin is a standard treatment, but newer agents like recombinant hirudin offer potential advantages.
Purpose of the Study:
- To investigate the efficacy and safety of recombinant hirudin compared to heparin in ACS patients.
- To evaluate antithrombin therapy in both primary treatment and post-thrombolysis settings for ACS.
Main Methods:
- A global, multifactorial clinical trial involving 12,000 patients.
- Comparison of standard heparin doses versus recombinant hirudin.
- Inclusion of patients with unstable angina and myocardial infarction (MI) unsuitable for thrombolysis, as well as post-thrombolysis patients.
Main Results:
- The GUSTO II trial is designed to provide significant data on antithrombin therapy outcomes.
- Results will elucidate the comparative effectiveness of heparin and recombinant hirudin in ACS management.
Conclusions:
- The findings will inform clinical practice guidelines for antithrombin use in ACS.
- This trial aims to establish the role of recombinant hirudin in managing acute coronary syndromes.
Abstract:
The GUSTO II trial will investigate the role of antithrombin therapy in acute coronary syndromes, comparing standard doses of heparin with the specific antithrombin agent recombinant hirudin. The two drugs will be compared as primary therapy in patients with unstable angina or patients with myocardial infarction (MI) unsuitable for thrombolysis, and as post thrombolysis treatment in patients who fulfil standard criteria for thrombolysis therapy. A total of 12,000 patients will be studied in a global, multifactorial trial.